A randomised controlled trial to evaluate the efficacy of vonoprazan for artificial ulcer healing after gastric endoscopic submucosal dissection

A randomised controlled trial to evaluate the efficacy of vonoprazan for artificial ulcer healing after gastric endoscopic submucosal dissection - The efficacy of vonoprazan for ESD-induced ulcer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019835

Enrollment

130

Registered

2015-11-18

Start date

2015-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric ulcer

Interventions

vonoprazan 20mg/day for 4 to 8 weeks p.o. rebamipide 300mg/day for 4 to 8 weeks p.o. lansoprazole 30mg/day for 4 to 8 weeks p.o. rebamipide 300mg/day for 4 to 8 weeks p.o.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20 to 89 who scheduled for ESD for gastric adenoma or early cancer

Exclusion criteria

Exclusion criteria: Patients with 1)the history of surgery for upper GI 2)concomitant administration of anticoagulants 3)concomitant administration of PPI 4)the history of radiotherapy or chemotherapy within 3 months 5)gastric hyperacidity such as Zollinger-Ellison syndorome 6)allergy to PPI or rebamipide

Design outcomes

Primary

Measure	Time frame
Cure rates of gastric ulcer at 4 weeks after treatment	—

Secondary

Measure	Time frame
Cure rates of gastric ulcer at 8 weeks after treatment, reduction rates of gastric ulcer at 4 and 8 weeks after treatment, incidence rate of delayed bleeding	—

Countries

Japan

Contacts

Public ContactKazuhiro Watanabe

National Center for Global Health and Medicine Gastroenterological medicine

kazuw0229@gmail.com03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026